Catalog No.
DHC04201
Expression system
Mammalian Cells
Species reactivity
Human
Host species
Human
Isotype
IgG1-kappa
Clonality
Monoclonal
Target
Plasma thromboplastin antecedent, PTA, Coagulation factor XI, F11, FXI
Concentration
1 mg/ml
Endotoxin level
Please contact with the lab for this information.
Purity
>95% as determined by SDS-PAGE.
Purification
Protein A/G purified from cell culture supernatant.
Accession
P03951
Applications
Research Grade Biosimilar
Form
Liquid
Storage buffer
0.01M PBS, pH 7.4.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.
Alternative Names
BAY 1213790, CAS: 2056878-75-0,FXI, FXIa
Clone ID
Osocimab
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial, PMID: 31935028
Osocimab: A Novel Agent in Preventing Venous Thromboembolism, PMID: 33105325
Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease, PMID: 32994051
Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI, PMID: 31655039
Anticoagulation in Atrial Fibrillation: Is a Paradigm Shift From Xa to XIa Inhibitors on the Horizon?, PMID:40439401
Compassionate Use of Osocimab in Preventing Thrombotic Complications Without Incremental Bleeding: A Case Report., PMID:40406075
Targeting factor XI as a compromise between thrombosis and bleeding., PMID:40357657
Potential New Treatments for Chronic Kidney Diseases: A Concise Review., PMID:39936428
A Systematic Review of Safety and Efficacy of Factor XI/XIa Inhibitors in Patients With ESKD on Hemodialysis., PMID:39810768
From the INVICTUS Trial to Current Considerations: It's Not Time to Retire Vitamin K Inhibitors Yet!, PMID:39598370
Pharmacokinetics and pharmacodynamics of the factor XIa-inhibiting antibody osocimab in healthy male East Asian volunteers: Results from two phase 1 studies., PMID:39308062
Therapeutic Potential of FXI Inhibitors: Hype or Hope?, PMID:39073551
Drug-Drug Interactions of FXI Inhibitors: Clinical Relevance., PMID:38534886
Anticoagulation with osocimab in patients with kidney failure undergoing hemodialysis: a randomized phase 2 trial., PMID:38365952
Venous Thromboembolism Prophylaxis in Major Orthopedic Surgeries and Factor XIa Inhibitors., PMID:37606428
Development of new anticoagulant in 2023: Prime time for anti-factor XI and XIa inhibitors., PMID:37422330
News at XI: moving beyond factor Xa inhibitors., PMID:37116752
Factor XI Inhibitors in Early Clinical Trials: A Meta-analysis., PMID:36841245
Pharmacotherapy for stroke prevention in nonvalvular atrial fibrillation: current strategies and future directions., PMID:36398362
Osocimab: A Novel Agent in Preventing Venous Thromboembolism., PMID:33105325
Turning Up to Eleven: Factor XI Inhibitors as Novel Agents to Maximize Safety and Maintain Efficacy in Thromboembolic Disease., PMID:32994051
Effect of Osocimab in Preventing Venous Thromboembolism Among Patients Undergoing Knee Arthroplasty: The FOXTROT Randomized Clinical Trial., PMID:31935028
Allosteric Inhibition as a New Mode of Action for BAY 1213790, a Neutralizing Antibody Targeting the Activated Form of Coagulation Factor XI., PMID:31655039
For research use only. Not for human or drug use.
